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A Prospective Follow-Up Study in a Consecutive Patient Population
Dominik Buckert, MD, Patricia Dewes, Thomas Walcher, MD, Wolfgang Rottbauer, MD,
Peter Bernhardt, MD
Ulm, Germany
O B J E C T I V E S The aim of this study was to assess the hypothesis that cardiac magnetic resonance
(CMR) myocardial perfusion imaging can provide incremental prognostic value over other risk factors
regarding the prediction of major cardiovascular events in a large, consecutive, and thereby unselected
population of patients presenting with stable angina pectoris.
B A C KG ROUND Recently, it has been shown that CMR provides good short-term prognosis in
patients with stable coronary heart disease. Reversible myocardial ischemia can be assessed using a
combination of perfusion and late gadolinium enhancement imaging. Data concerning intermediate-
term prognostic information, especially on major clinical endpoints such as cardiac death or myocardial
infarction, are limited.
METHOD S From 2003 to 2007, consecutive patients with stable angina pectoris who underwent
adenosine perfusion CMR were enrolled unless they met the predeﬁned exclusion criteria. Myocardial
perfusion imaging by adenosine stress and late gadolinium enhancement was assessed using a 1.5-T
whole-body CMR scanner. Follow-up information concerning the combined endpoint of cardiac death,
nonfatal myocardial infarction, and stroke was obtained from patients, general practitioners, or treating
hospitals, respectively.
R E S U L T S In our study, 1,229 consecutive patients were enrolled. The mean follow-up period was
4.2  2.1 years. During this time, 88 primary endpoints occurred. In patients with reversible perfusion
deﬁcits, signiﬁcantly more cardiac deaths (p  0.0001) and nonfatal myocardial infarctions (p  0.001)
were observed than in the control group. On multivariate analysis, reversible perfusion deﬁcit was the
strongest independent predictor for an event, with a 3-fold increased risk. Moreover, the absence of a
perfusion deﬁcit was shown to exhibit high negative predictive value.
CONC L U S I O N S Adenosine perfusion CMR provides excellent risk stratiﬁcation and intermediate-
term prognostic value in patients with stable coronary artery disease. The presence of a myocardial
perfusion deﬁcit is an incremental prognostic risk factor over other risk factors. (J Am Coll Cardiol Img
2013;6:56–63) © 2013 by the American College of Cardiology Foundation
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57oninvasive testing for myocardial ischemia
in patients presenting with stable angina
pectoris is recommended before coronary
revascularization (1). However, many pa-
ients undergoing revascularization lack prior non-
nvasively documented ischemia (2).
Cardiac magnetic resonance (CMR) offers dif-
erent advantages in comparison with other nonin-
asive stress tests because of its high spatial resolu-
ion, image contrast, and lack of ionizing radiation.
denosine perfusion CMR has been extensively
tudied in recent years. Its high diagnostic accuracy
o detect coronary artery stenoses in patients with
uspected coronary artery disease (CAD) has been
roved (3–9). Recent data suggest that CMR myo-
ardial perfusion imaging provides good short-term
rognosis for cardiac events in patients with sus-
ected CAD (10–15). Most of these latter studies
ncluded only specific subsets of patients (e.g., those
resenting with acute chest pain). Others defined
ather soft composite endpoints, including rehospi-
alization, heart failure, revascularization, and
50% coronary stenosis. Only 1 study presented a
arge population of consecutive patients who under-
ent stress CMR for suspicion of coronary stenosis
15). That study found that the presence of abnor-
al CMR characteristics, including a reversible
erfusion deficit, was a strong predictor of myocar-
ial events during a mean follow-up period of 2.6
ears.
The aim of our prospective study was to evaluate
ntermediate-term adenosine perfusion CMR prog-
osis for predicting cardiovascular events (cardiac
eath and nonfatal myocardial infarction) in a
onsecutive and large patient cohort presenting
ith stable angina pectoris. The incremental
ntermediate-term prognostic value over other risk
actors should be evaluated and needs to be proved.
M E T H O D S
Patients. From 2003 to 2007, we screened consec-
tive patients with stable angina pectoris as defined
y American College of Cardiology and American
eart Association guidelines (16) who underwent
denosine perfusion CMR for enrollment. Patients
ere eligible if they were suspected of having CAD
r progression of known CAD. Exclusion criteria
ere cardiac or respiratory instability, concomitant
imiting disease (e.g., cancer), high-degree heart
alve or pulmonary disease, pregnancy, inability to
ive informed written consent, age 18 years, and
yocardial infarction within the past 3 months.atients were instructed to refrain from methylxan-
hine agents for at least 24 hours before CMR
xamination.
CMR study. CMR imaging was performed using a
.5-T whole-body clinical magnetic resonance
canner (Intera; Philips Medical Systems, Best, the
etherlands) using a cardiac 5-element phased-
rray receiver coil. Functional imaging of the left
nd right ventricles was performed in the contigu-
us short-axis orientation, covering the ventricles
rom the base to the apex, using a steady-state free
recession sequence (repetition time 5.1 ms, echo
ime 2.2 ms, flip angle 55°, voxel size 1.6 1.6 mm,
lice thickness 8 mm, no interslice gap, acquisition
n end-expiration breath-hold).
Adenosine was given intravenously at a constant
ate of 140 g/kg/min for 3 min. At maximal
vasodilation, first-pass imaging of 0.1 mmol/kg of a
gadolinium-based contrast agent (Magnevist; Bayer
Schering Pharma AG, Berlin, Germany) was visu-
alized using a balanced fast-field echo sequence
(repetition time 2.6 ms, echo time 1.3 ms, saturate
pre-pulse with 100-ms delay, flip angle 50°, 40
dynamics, voxel size 2.8  2.9 mm, slice
hickness 10 mm) in 3 short-axis views
apical, midventricular, and basal) cover-
ng 16 myocardial segments (17). An ad-
quate vasodilator response was defined as
n increase in heart rate of more than 10%
r a decrease in systolic blood pressure of
ore than 10%. If the predefined vasodi-
ator response was not observed within 3 min, the
denosine infusion rate was increased by 10% for
nother minute, until an adequate response was
bserved. A second perfusion study using the same
arameters and a second bolus of contrast agent (0.1
mol/kg) were used 10 min later at rest to allow
etter discrimination of perfusion deficits during
denosine in comparison with rest. Ten minutes
fter the second contrast bolus, an inversion recov-
ry gradient-echo sequence was performed in the
ontinuous short-axis view for the evaluation of late
adolinium enhancement (repetition time 7.1 ms,
cho time 3.2 ms, voxel size 1.6  1.6 mm, slice
thickness 8 mm). Inversion time was individually
adjusted for complete nulling of the myocardium.
CMR analysis. Volumetric end-diastolic and end-
systolic left and right ventricular volumes were
acquired from the contiguous cine short-axis stack
using the standard software provided by the man-
ufacturer of the CMR system (ViewForum; Philips
Medical Systems), manually drawing epicardial and
A B B
A N D
CAD
CMR
resonendocardial contours.R E V I A T I O N S
A C R O N YM S
coronary artery disease
cardiac magnetic
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58Regional wall motion was assessed in consensus by
2 observers using a recommended wall motion score
(18). Therefore, each segment was scored as follows:
1  normal or hyperkinesis, 2  hypokinesis, 3 
kinesis, 4  dyskinesis, and 5  aneurysmal.
The perfusion images were similarly interpreted
y 2 different observers, blinded to the patient’s
istory and symptoms, in consensus. Adenosine and
est perfusion images were displayed simultaneously
sing the 16-segment model. Regional hypoen-
ancement  25% that was present in the dynamic
evealing the maximal extent of regional hypoen-
ancement in any segment at stress, but not visible
t rest perfusion, and without corresponding late
adolinium enhancement, was considered patho-
ogical and defined as a reversible perfusion deficit.
n case of late gadolinium enhancement, a perfusion
eficit extending the area of late gadolinium en-
ancement was defined as a reversible perfusion
eficit. Figure 1 provides an example of a reversible
nd no perfusion deficit with corresponding rest
erfusion and late gadolinium enhancement.
Follow-up. Follow-up was determined from patients’
interviews by telephone or in the outpatient clinic, by
hospital chart reviews, or by contact with general
Figure 1. CMR Examples
(A) Example of a reversible perfusion deﬁcit seen in the anterior an
perfusion deﬁcit at rest and late gadolinium enhancement. (B) Exam
rest and without late gadolinium enhancement.practitioners or treating hospitals. The combined pri-mary endpoint was defined as cardiac death, nonfatal
myocardial infarction, and stroke. Cardiac death was
defined as death from any cardiac cause (e.g., myocar-
dial infarction, ventricular fibrillation or other lethal
arrhythmia, heart failure) and sudden unexplainable
death. Myocardial infarction was defined by a 2-fold or
more increase of troponin. After the occurrence of an
adverse event, follow-up was ended for the individual
patient.
Statistical analysis. For categorical variables, the
Fisher exact test was used to test differences be-
tween the groups with and without perfusion deficit
and between patients with and without the end-
point during the observation period. Continuous
variables were compared using 2-tailed t tests after
being tested for a normal distribution using the
D’Agostino-Pearson test. Univariate and multivar-
iate regression analysis was performed using Cox
proportional hazards models to estimate the predic-
tive value of the variables. Hazard ratios and corre-
sponding 95% confidence intervals are provided. Chi-
square values were calculated with the Cox
proportional hazards regression overall model fit. For
multivariate analysis, stepwise forward selection was
used. Continuous variables are reported as mean 
teroseptal segments during adenosine without corresponding
of a patient without a perfusion deﬁcit during adenosine and atd an
pleSD. A p value 0.05 was judged significant. Cumu-
t
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59lative event curves were compared by the Kaplan-
Meier method using a log-rank test. Statistical anal-
ysis was performed using commercially available
software (MedCalc; Mariakerke, Belgium).
R E S U L T S
Patients. A total of 1,229 patients were enrolled in
he study. Seventy-seven (6.3%) were lost to
ollow-up during the follow-up period. A total of
,152 patients whose follow-up information was
btained formed the study group. The mean age
as 61.7  11.6 years. The mean follow-up period
as 4.2  2.1 years. At 6 years of follow-up, about
7% of the patients with reversible perfusion deficits
ere still under observation. In the group of patients
ithout perfusion deficits, this percentage was 96%.
hree hundred twenty-eight women (28.5%) and
24 men (71.5%) were included. Clinical and de-
ographic characteristics, including cardiovascular
isk factors and prior cardiac events, are provided in
able 1. Figure 2 provides an overview of screened
nd enrolled patients and their outcomes.
CMR results. CMR examinations were performed in
ll patients without major complications. No image
as excluded because of insufficient image quality.
The mean left ventricular end-diastolic volume
Table 1. Patient Characteristics and CMR Results, Including Com
Variable
Total
(n  1,152)
Reversible
Deﬁ
(n 
Age (yrs) 61.7 11.6 64.1
Women 328 (28.5%) 71 (2
Cardiovascular risk factors
BMI (kg/m2) 26.83.8 27.1
Hypertension 729 (63.3%) 221 (7
Smoking 271 (23.5%) 75 (2
Hyperlipidemia 657 (57.0%) 213 (6
Diabetes mellitus 239 (20.7%) 78 (2
Morise risk score 13.9 4.0 14.8
Prior cardiac events
Myocardial infarction 411 (35.7%) 142 (4
PCI 466 (40.5%) 166 (5
CABG 139 (12.1%) 56 (1
CMR
LVEDV (ml) 143 49 142
LVEF (%) 63.7 13.0 63.0
Wall motion score 20.1 5.3 20.9
Late enhancement 473 (41.1%) 184 (5
Values are mean  SD or n (%).
BMI  body mass index; CABG  coronary artery bypass graft; CMR  cardia
ventricular ejection fraction; PCI  percutaneous coronary intervention.as 143  49 ml, and the mean ejection fraction ias 63.7  13.0%. Reversible perfusion deficits
ere observed in 310 patients (26.9%) and late
adolinium enhancement in 473 (41.1%).
Patients with reversible perfusion deficits were sig-
ificantly older (64.1  11.0 years vs. 60.7  11.7
ears) and predominantly men (239 [77.1%] vs. 585
69.5%]). Hypertension, hyperlipidemia, and diabetes
ere present significantly more often in patients with
eversible perfusion deficits than in those without.
urthermore, patients with reversible perfusion defi-
its more often had histories of myocardial revascular-
zation and myocardial infarction compared with pa-
ients without reversible perfusion deficits. All in all,
he presence of a reversible perfusion deficit was
orrelated with other known risk factors for coronary
eart disease, as would be suspected. Concerning
ther CMR characteristics of interest, higher wall
otion scores were observed, and late gadolinium
nhancement was more often present in patients with
han without reversible perfusion deficits. All data and
values are provided in Table 2.
As can be seen in Table 2, the primary endpoint
as observed in 51 patients (16.5%) with and in 37
4.4%) without reversible perfusion deficits. Pa-
ients with events were significantly older, were
redominantly male, more often had diabetes mel-
itus, and more often had histories of myocardial
ison of Patients With and Without Perfusion Deﬁcits
fusion
)
No Reversible Perfusion
Deﬁcit
(n  842) p Value
.0 60.8 11.7 0.0001
) 257 (30.5%) 0.0122
26.7 3.9 0.1117
) 508 (60.3%) 0.0006
) 196 (23.3%) 0.8052
) 444 (52.7%) 0.0001
) 161 (19.1%) 0.0271
13.5 4.1 0.001
) 269 (31.9%) 0.0001
) 300 (35.6%) 0.0001
) 83 (9.9%) 0.0003
143 50 0.8520
.4 64.0 12.5 0.2530
19.7 5.3 0.0014
) 289 (34.3%) 0.0001
agnetic resonance; LVEDV  left ventricular end-diastolic volume; LVEF  leftpar
Per
cit
310
11
2.9%
3.6
1.3%
4.2%
8.7%
5.2%
3.5
5.8%
3.5%
8.2%
47
14
5.4
9.4%
c mnfarction, percutaneous coronary intervention, and
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60coronary bypass operations. End-diastolic volumes
were significantly larger, ejection fractions lower,
wall motion scores increased, and late enhancement
more often present in patients with compared with
those without the primary endpoint.
N=1,438
N=1,152
N=1,229
N=310 reversible
perfusion deficit
N=51 primary
endpoint
N=259 without
primary
endpoint
Figure 2. Flowchart of Patient Recruitment, Inclusion, and Follo
Table 2. Comparison Between Patients With and
Without Events
Variable
Event
(n  88)
No Event
(n  1,064)
p
Value
Age (yrs) 66.2 11.0 61.3 11.6 0.0001
Women 17 (19.3%) 311 (29.2%) 0.0495
Cardiovascular risk factors
BMI (kg/m2) 27.0 3.8 26.8 3.8 0.6666
Hypertension 63 (71.6%) 666 (62.6%) 0.1070
Smoking 24 (27.3%) 247 (23.2%) 0.4323
Hyperlipidemia 57 (64.8%) 600 (56.4%) 0.1453
Diabetes mellitus 33 (37.5%) 206 (19.4%) 0.0002
Morise risk score 14.6 3.6 13.8 4.0 0.088
Prior cardiac events
Myocardial infarction 46 (52.3%) 365 (34.3%) 0.0011
PCI 49 (55.7%) 417 (39.2%) 0.0031
CABG 19 (21.6%) 120 (11.3%) 0.0094
CMR
LVEDV (ml) 159 67 142 47 0.0016
LVEF (%) 56.3 18.1 64.3 12.3 0.0001
Wall motion score 23.4 7.7 19.8 5.0 0.0001
Reversible perfusion deﬁcit 51 (58.0%) 259 (24.3%)0.0001
Late enhancement 58 (65.9%) 415 (39.0%)0.0001
Values are mean  SD or n (%).aAbbreviations as in Table 1.Predictors of the primary endpoint. During the
ollow-up period, 88 patients (7.6%) had the com-
ined primary endpoint. About 45% of the end-
oints occurred in the first 2 years after the CMR
xamination (about 30% in the first year and the
ther 15% in the second year). In every additional
ear of follow-up, the annual event rate was approx-
mately 10%. Cardiovascular death (29 [9.4%] vs.
7 [2.0%]) and nonfatal myocardial infarction (18
5.8%] vs. 15 [1.8%]) occurred significantly more
ften in patients with than in those without revers-
ble perfusion deficits. The incidence of stroke was
ot significantly different (4 [1.3%] vs. 5 [0.6%]).
aplan-Meier curves for event-free survival are
llustrated in Figure 3 and show event-free survival
f 83.5% in patients with versus 95.6% in those
ithout reversible perfusion deficits during the
bservation period. Univariate analysis of potential
redictors for the occurrence of the primary end-
oint is provided in Table 3. Significant associa-
ions were found for age, sex, diabetes mellitus,
istory of myocardial infarction and revascular-
zation, left ventricular end-diastolic volume and
jection fraction, wall motion score, reversible
erfusion deficit, and late gadolinium enhance-
ent. The chi-square-test yielded the highest
alue for the presence of a reversible perfusion
eficit. Chi-square values are also provided in
able 3. On multivariate analysis, age, left ven-
ricular end-diastolic volume, ejection fraction,
eened
ow-up
rolled
N=37 primary
endpoint
N=842 no reversible
perfusion deficit
N=805 without
primary
endpoint
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61significant variables (Table 4). Cox proportional
hazards regression revealed that reversible perfu-
sion deficit yielded the highest coefficient, prov-
ing the incremental value of reversible perfusion
deficit over the other variables.
D I S C U S S I O N
The presence of a reversible myocardial perfusion
deficit as detected by the combination of adenosine
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Figure 3. Kaplan-Meier Survival Graph
Kaplan-Meier survival graph of event-free survival showing patients
event rate compared with patients with reversible perfusion deﬁcits
Table 3. Univariate Analysis of Predictors of the Primary
Endpoint
Variable HR 95% CI
p
Value
Chi-
Square
Age 1.04 1.02–1.06 0.0002 15.9
Female 0.58 0.34–0.99 0.0456 4.4
Diabetes mellitus 2.39 1.55–3.67 0.0001 12.7
Morise risk score 1.05 0.99–1.11 0.0881 2.9
Myocardial
infarction
2.04 1.34–3.09 0.0009 9.6
PCI 1.89 1.24–2.78 0.0030 7.3
CABG 2.10 1.27–3.48 0.0042 6.1
History of coronary
artery disease
2.11 1.31–3.39 0.0023 10.3
LVEDV 1.01 1.00–1.01 0.0010 8.6
LVEF 0.96 0.95–0.98 0.0001 27.4
Wall motion score 1.09 1.06–1.12 0.0001 28.2
Reversible
perfusion deﬁcit
3.94 2.58–6.00 0.0001 40.1
Late enhancement 3.17 2.01–4.99 0.0001 26.8CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in Table 1.perfusion and late gadolinium CMR provides excel-
lent prognostic stratification of patients with CAD,
consistent with other recent reports (10–14). In a
multivariate analysis, we showed that the presence of a
reversible perfusion deficit was associated with a
3-fold increased risk for death or nonfatal myocardial
infarction, in accordance with another study present-
ing a 3-fold increased risk (11). In contrast to the
atter study, which included only 14% patients with
ypical, 49% with atypical angina, and one-third with
onanginal symptoms, all of our patients had anginal
ymptoms, representing a higher likelihood of myo-
ardial ischemia. We showed that reversible perfusion
eficit was the strongest multivariate predictor of
ajor adverse cardiovascular events, with incremental
rognostic value over other cardiovascular risk factors.
e included consecutive patients with stable angina
ectoris and suspected CAD or progression of known
No reversible
perfusion deficit
<0.0001
Reversible
perfusion deficit
3000
hout reversible perfusion deﬁcits to have a signiﬁcantly lower
 0.0001).
Table 4. Multivariate Analysis of Predictors of the Primary
Endpoint
Variable HR 95% CI
p
Value
Age 1.02 1.00–1.05 0.0385
Diabetes mellitus 1.34 1.06–1.67 0.0127
Wall motion score 1.07 0.98–1.09 0.0001
Reversible perfusion deﬁcit 3.21 2.06–5.00 0.0001
Variables that were excluded by the stepwise forward selection included sex,
history of myocardial infarction, PCI, CABG, known coronary artery disease,
LVEDV, LVEF, and late gadolinium enhancement.P
witAbbreviations as in Tables 1 and 3.
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62CAD without further pre-selection, so our study
population consisted of patients with low to high risk
for CAD, which underlines the benefit of adenosine
stress CMR concerning risk stratification under ev-
eryday conditions. Hence, this is 1 of the strengths of
our study, evaluating a routine clinical patient cohort
in contrast to other studies.
Coronary angiography is still regarded as the gold
standard for the evaluation of coronary artery stenosis.
Because it has been observed that there is a discrep-
ancy between angiographic and clinical findings (19),
this has led to changes in current guidelines, which
recommend the use of noninvasive stress testing in
patients with stable angina pectoris for therapy deci-
sion (1,16). Nonetheless, current medical practice is
still more commonly based on assessment of the
anatomical degree of coronary artery stenosis (2,20),
hich is mostly done visually. This may lead to
nterventions that provide no benefit for patients.
ence, all of our patients were treated according to
he current guidelines. This means that most of the
atients with reversible perfusion deficits underwent
nterventional therapy, unless they exhibited contrain-
ications. Patients without perfusion deficit under-
ent coronary revascularization treatment only if op-
imal medical treatment could not relieve their
ymptoms properly (16). Nevertheless, patients with
erfusion deficits had a higher event rate than those
ithout perfusion deficits, indicating the higher sever-
ty of their coronary disease. The question of whether
MR-guided therapy has a prognostic impact and1991;18:959–65. tic performance of strur study and must be evaluated in further studies
ith other designs.
In particular, the negative predictive value of a
tress test must be very high to avoid cardiovascular
vents in patients with negative results. This is
andatory in patients with stable angina pectoris to
void the necessity of invasive testing. Exercise
chocardiography and scintigraphy are the most
ommon noninvasive stress tests, but they have
alse-negative rates of up to 30% (21). In our study,
-year event-free survival in case of absent reversible
erfusion deficit was 95.6%, proving the very high
egative predictive value of CMR in an unselected
onsecutive cohort of patients.
We showed that CMR provides incremental
rognostic information in patients at low to high
isk for coronary events. Moreover, CMR offers
ther important information in a single exam about
eft ventricular function, viability, heart valve dis-
ase, and anatomy, leading to further optimization
f individual therapy decisions.
Further studies are warranted to determine
hether CMR can prevent redundant invasive cor-
nary angiographic studies and to what extent this
ould result in patient benefit and possible savings
f health care expenses.
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